Citations

Clear

499 citation(s) found for "Tracy, PB".

Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium
Easton, Douglas F. , Stanford, Janet L. , Ostrander, Elaine A. , Schleutker, Johanna , Schaid, Daniel J. , Thibodeau, Stephen N. , Dörk, Thilo , Neal, David E. , Cox, Angela , Maier, Christiane, Guy, Michelle, Lophatananon, Artitaya, Kedda, Mary-Anne, Spurdle, Amanda B. , Steginga, Suzanne K., John, Esther M. , Giles, Graham G. , Chappuis, Pierre O. , Hutter, Pierre, Foulkes, William D. , Hamel, Nancy , Salinas, Claudia A., Karyadi, Danielle M. , Johanneson, Bo, Wahlfors, Tiina , Tammela, Teuvo L.J. , Corral, Román, McDonnell, Shannon K. , Schürmann, Peter , Meyer, Andreas , Kuefer, Rainer, Leongamornlert, Daniel , Tymrakiewicz, Malgorzata, Liu, Jo‐Fen , O’Mara, Tracy A. , Gardiner, Robert A. , Aitken, Joanne F. , Joshi, Amit D. , Severi, Gianluca , English, Dallas R. , Southey, Melissa C. , Edwards, Stephen M., Olama, Ali Amin Al , Eeles, Rosalind A. , Donovan, Jenny , Chambers, Suzanne K. , Kote‐Jarai, Zsofia , Ingles, Sue A. , Vogel, W. , Muir, Kenneth , Hopper, John L. , Koopmeiners, Joseph Stephen , Stern, Mariana Carla , Dörk, Thilo , Giles, Graham G , Spurdle, Amanda B , Foulkes, William D , Eeles, Rosalind A , John, Esther M , Southey, Melissa C , English, Dallas R , Donovan, Jenny L , Schleutker, Johanna , O'Mara, Tracy A , Cox, Angela , Severi, Gianluca , McDonnell, Shannon K

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | August 15, 2008 | Volume: 17 | Issue: 8 | Pages: 2052-2061

10.1158/1055-9965.epi-08-0317 | PMID 18708398 Get It

Abstract A recent genome-wide association study found that genetic variants on chromosomes 3, 6, 7, 10, 11, 19 and X were associated with prostate cancer risk. We evaluated the most significant single-nucleotide polymorphisms (SNP) in these loci using a worldwide consortium of 13 groups (PRACTICAL). Blood DNA from 7,370 prostate cancer cases and 5,742 male controls was analyzed by genotyping assays. Odds ratios (OR) associated with each genotype were estimated using unconditional logistic regression. Six of the seven SNPs showed clear evidence of association with prostate cancer (P = 0.0007-P = 10−17). For each of these six SNPs, the estimated per-allele OR was similar to those previously reported and ranged from 1.12 to 1.29. One SNP on 3p12 (rs2660753) showed a weaker association than previously reported [per-allele OR, 1.08 (95% confidence interval, 1.00-1.16; P = 0.06) versus 1.18 (95% confidence interval, 1.06-1.31)]. The combined risks associated with each pair of SNPs were consistent with a multiplicative risk model. Under this model, and in combination with previously reported SNPs on 8q and 17q, these loci explain 16% of the familial risk of the disease, and men in the top 10% of the risk distribution have a 2.1-fold increased risk relative to general population rates. This study provides strong confirmation of these susceptibility loci in multiple populations and shows that they make an important contribution to prostate cancer risk prediction. (Cancer Epidemiol Biomarkers Prev 2008;17(8):2052–61)
Medullary Thyroid Carcinoma without Marked Elevation of Calcitonin: A Diagnostic and Surveillance Dilemma
Ocal, Idris Tolgay, Cox, Heather, Wang, Tracy S. , Sosa, Julie Ann , Roman, Sanziana A.

Mayo Clinic

Thyroid | July 23, 2008 | Volume: 18 | Issue: 8 | Pages: 889-894

10.1089/thy.2007.0413 | PMID 18651827 Get It

Primary Leiomyosarcoma of the Thyroid Gland
Ocal, Idris Tolgay, Oxley, Keri, Wang, Tracy S. , Sosa, Julie Ann

Mayo Clinic

Thyroid | March 17, 2008 | Volume: 18 | Issue: 4 | Pages: 425-428

10.1089/thy.2007.0276 | PMID 18346004 Get It

Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
Doolittle, Nancy D., Abrey, Lauren E. , Shenkier, Tamara , Tali, Siegal, Bromberg, Jacoline E. C. , Neuwelt, Edward A. , Soussain, Carole , Jahnke, Kristoph, Illerhaus, Gerald , Schiff, David , Batchelor, Tracy T. , Montoto, Silvia , Kraemer, Dale F., Zucca, Emanuele , Johnston, Patrick , Montoto, Silvia , Zucca, Emanuele

Mayo Clinic

Blood | October 25, 2007 | Volume: 111 | Issue: 3 | Pages: 1085-1093

10.1182/blood-2007-07-101402 | PMID 17962515 Get It

Abstract Isolated central nervous system (CNS) relapse involving the brain parenchyma is a rare complication of systemic non-Hodgkin lymphoma. We retrospectively analyzed patient characteristics, management, and outcomes of this complication. After complete response to initial non-Hodgkin lymphoma treatment, patients with isolated CNS relapse with the brain parenchyma as initial relapse site were eligible. Patients with isolated CNS relapse involving only the cerebrospinal fluid were not eligible. Information on 113 patients was assembled from 13 investigators; 94 (83%) had diffuse large B-cell lymphoma. Median time to brain relapse was 1.8 years (range, 0.25-15.9 years). Brain relapse was identified by neuroimaging in all patients; in 54 (48%), diagnostic brain tumor specimen was obtained. Median overall survival from date of brain relapse was 1.6 years (95% confidence interval, 0.9-2.6 years); 26 (23%) have survived 3 years or more. Median time to progression was 1.0 year (95% confidence interval, 0.7-1.7 years). Age less than 60 years (P = .006) at relapse and methotrexate use (P = .008) as front-line treatment for brain relapse were significantly associated with longer survival in a multivariate model. Our results suggest systemic methotrexate is the optimal treatment for isolated CNS relapse involving the brain parenchyma. Long-term survival is possible in some patients.
Perioperative Cardiac Arrests in Children between 1988 and 2005 at a Tertiary Referral Center
Flick, Randall P., Harrison, Tracy E. , Gleich, Stephen J. , Schroeder, Darrell R. , Hanson, Andrew C. , Buenvenida, Shonie L., Warner, David O., Šprung, Juraj , Schroeder, Darrell

Mayo Clinic

Anesthesiology | January 22, 2007 | Volume: 106 | Issue: 2 | Pages: 226-237

10.1097/00000542-200702000-00009 | PMID 17264715 Get It

Background The objective of this study was to determine the incidence and outcome of perioperative cardiac arrest (CA) in children younger than 18 yr undergoing anesthesia for noncardiac and cardiac procedures at a tertiary care center. Methods After institutional review board approval (Mayo Clinic, Rochester, Minnesota), all patients younger than 18 yr who had perioperative CA between November 1, 1988, and June 30, 2005, were identified. Perioperative CA was defined as a need for cardiopulmonary resuscitation or death during anesthesia care. A cardiac procedure was defined as a surgical procedure involving the heart or great vessels requiring an incision. Results A total of 92,881 anesthetics were administered during the study period, of which 4,242 (5%) were for the repair of congenital heart malformations. The incidence of perioperative CA during noncardiac procedures was 2.9 per 10,000, and the incidence during cardiac procedures was 127 per 10,000. The incidence of perioperative CA attributable to anesthesia was 0.65 per 10,000 anesthetics, representing 7.5% of the 80 perioperative CAs. Both CA incidence and mortality were highest among neonates (0-30 days of life) undergoing cardiac procedures (incidence: 435 per 10,000; mortality: 389 per 10,000). Regardless of procedure type, most patients who experienced perioperative CA (88%) had congenital heart disease. Conclusion The majority of perioperative CAs were caused by factors not attributed to anesthesia, in distinction to some recent reports. The incidence of perioperative CA is many-fold higher in children undergoing cardiac procedures, suggesting that definition of case mix is necessary to accurately interpret epidemiologic studies of perioperative CA in children.
P1–347: A novel resequencing technique allows quantitation of heteroplasmy in MTDNA sequence variants found in AD patients
Coon, Keith D., Valla, Jon, Szelinger, Szabolcs , Schneider, Lonnie , Niedzielko, Tracy L., Brown, Kevin M., Casseli, Richard J., Reiman, Eric M. , Stephan, Dietrich , Pearson, John V. , Stafford, Phillip , Papassotiropoulos, Andreas

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_7 | Pages: No page available

10.1016/j.jalz.2006.05.725 Get It

Genetic Counseling Outcomes: Perceived Risk and Distress After Counseling for Hereditary Colorectal Cancer
Codori, Ann‐Marie, Waldeck, Tracy, Petersen, Gloria M. , Miglioretti, Diana L. , Trimbath, Jill D., Tillery, Miriam, Miglioretti, Diana L

Mayo Clinic

Journal of Genetic Counseling | June 13, 2005 | Volume: 14 | Issue: 2 | Pages: 119-132

10.1007/s10897-005-4062-2 | PMID 15959643 Get It

AbstractGenetic counseling may turn risk information into cancer prevention behavior by modifying health beliefs and cancer‐related distress. We assessed the effect of genetic counseling on these factors in 101 adult first‐degree‐relatives of colorectal cancer patients from families with known or suspected hereditary nonpolyposis colorectal cancer. Before counseling and once afterward, subjects completed self‐report measures of perceived lifetime risk and cancer‐distress. Most persons overestimated their cancer risk, and higher perceived risk was associated with believing that colorectal cancer cannot be prevented. Individual perceived risk changed after counseling, although mean perceived risk was unchanged. After adjusting for baseline risk, older persons and those with higher estimated objective cancer risk had larger postcounseling decreases. Distress after counseling was positively correlated with baseline distress and anxiety symptoms, and inversely correlated with tolerance for ambiguity. The findings suggest counseling interventions that should increase the likelihood of screening and offer hypotheses for future research.
Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group
Shenkier, Tamara , Blay, Jean‐Yves , Poortmans, Philip , Thiel, Eckhard, Jahnke, Kristoph, Abrey, Lauren E. , Neuwelt, Edward A. , Tsang, Richard , Batchelor, Tracy T. , Ferreri, Andrés J.M. , O’Brien, Peter, Rubenstein, James L. , O’Neill, Brian Patrick , Harris, Nancy L. , Ponzoni, Maurilio , Connors, Joseph M. , Blay, Jean-Yves

Mayo Clinic

Journal of Clinical Oncology | March 30, 2005 | Volume: 23 | Issue: 10 | Pages: 2233-2239

10.1200/jco.2005.07.109 | PMID 15800313 Get It

Purpose To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL). Patients and Methods A retrospective series of patients with TPCNSL was compiled from twelve cancer centers in seven countries. Results We identified 45 patients with a median age of 60 years (range, 3 to 84 years). Twenty (44%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Twenty-six (58%) had involvement of a cerebral hemisphere and sixteen (36%) had lesions of deeper sites in the brain. Serum lactate dehydrogenase was elevated in 7 (32%) of 22 patients, and CSF protein was elevated in 19 of 24 patients (79%) with available data. The median disease-specific survival (DSS) was 25 months (95% CI, 11 to 38 months). The 2- and 5-year DSS were 51% (95% CI, 35% to 66%) and 17% (95% CI, 6% to 34%), respectively. Univariate and multivariate analyses were conducted for age (≤ 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no). Only PS and MTX use were significantly associated with better outcome with hazard ratios of 0.2 (95% CI, 0.1 to 0.4) and 0.4 (95% CI, 0.2 to 0.8), respectively. Conclusion This is the largest series ever assembled of TPCNSL. The presentation and outcome appear similar to that of B cell PCNSL. PS 0 or 1 and administration of MTX are associated with better survival.
Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients
Leong, Tracy L. , Bone, Nancy D., Vesole, David H., Greipp, Philip R., Ness, Brian G. Van , Oken, Martin M., Kyle, Robert A. , Kay, Neil E.

Mayo Clinic

Blood | July 27, 2002 | Volume: 98 | Issue: 1 | Pages: 23-28

10.1182/blood.v98.1.23 | PMID 11418458 Get It

AbstractPreviously, it was reported that patients with multiple myeloma (MM) who have higher baseline levels of blood CD4+or CD19+ cells have longer survival. This article extends the analysis of immune cell levels and survival in a large cohort (N = 504) of patients with MM entered on Eastern Cooperative Oncology Group (ECOG) phase 3 trial (9486). Newly diagnosed patients with MM received 2 cycles of vincristine, bischloroethylnitrosourea, melphalan, cytoxan, prednisone (VBMCP) and were treated on one of 3 randomized arms: VBMCP with either interferon or high-dose cyclophosphamide, or VBMCP alone. Blood immune cell levels were studied at trial entry (baseline), after 2 cycles of chemotherapy, after 2 years of therapy, and at relapse. Baseline CD3+, CD4+, CD8+, CD19+, and CD4+ subset cell levels were all positively associated with survival (P = .0087 toP < .0001). A multivariate analysis incorporating CD4+ and CD19+ cell levels defined 3 separate groups of patients with MM to survival outcome. Higher CD19+ blood levels were positively associated with MM-patient survival at entry to the study, at year 2, and at relapse (P < .0001 at all 3 timepoints). Patients with MM had evidence of immune cell reconstitution after 2 years of therapy, but the rate and extent of recovery was greater for CD8+, which was greater than CD4+, which was greater than CD19+. This latter data affirms the positive relationship between the quantitative status of the blood immune system in MM and survival. In addition, the importance of the CD19+ blood cells to survival is evident throughout the course of MM. Therapeutic efforts to maintain an intact immune system may be crucial in maximizing chemotherapeutic and/or immunotherapy efforts in this disease.